Batroxobin is a thrombin-like serine protease from the venom of the Bothrops atrox and Bothrops moojeni snake species.Sirtuin 1(Sirt1)has been shown to play an important role in neuroprotection after traumatic brain i...Batroxobin is a thrombin-like serine protease from the venom of the Bothrops atrox and Bothrops moojeni snake species.Sirtuin 1(Sirt1)has been shown to play an important role in neuroprotection after traumatic brain injury.However,its underlying mechanism of action remains poorly understood.The purpose of this study was to investigate whether the mechanism by which batroxobin participates in the activation of astrocytes is associated with Sirt1.Mouse models of nigrostriatal pathway injury were established.Immediately after modeling,mice were intraperitoneally administered 39 U/kg batroxobin.Batroxobin significantly reduced the expression of cleaved caspase-3 in both the substantia nigra and striatum,inhibited neuronal apoptosis,and promoted the recovery of rat locomotor function.These changes coincided with a remarkable reduction in astrocyte activation.Batroxobin also reduced Sirt1 expression and extracellular signal-regulated kinase activation in brain tissue.Intraperitoneal administration of the Sirt1-specific inhibitor EX527(5 mg/kg)30 minutes prior to injury could inhibit the abovementioned effects.In mouse astrocyte cultures,1 ng/mL batroxobin attenuated interleukin-1β-induced activation of astrocytes and extracellular signal-regulated kinase.EX527 could also inhibit the effects of batroxobin.These findings suggest that batroxobin inhibits astrocyte activation after nigrostriatal pathway injury through the Sirt1 pathway.This study was approved by the Animal Ethics Committee of China Medical University,China(approval No.CMU2020037)on July 19,2015.展开更多
Despite advances in diagnostic and therapeutic technologies for cardiovascular diseases(CVDs),it remains a leading cause of mortality and morbidity worldwide.This underscores the urgency for innovative approaches aimi...Despite advances in diagnostic and therapeutic technologies for cardiovascular diseases(CVDs),it remains a leading cause of mortality and morbidity worldwide.This underscores the urgency for innovative approaches aiming at early and precise detection and treatment of CVDs to reduce the disease burden.Iron oxide nanoparticles(IONPs),with their unique magnetism and bioproperties,have shown great potential in this regard.In this review,we will begin with a brief overview of the synthesis and properties of IONPs.We will then focus on the latest applications of IONPs in CVDs,including diagnosis and treatment.The use of IONPs in the integration of diagnosis and treatment for CVDs is a promising field,and will be addressed in a separate section.The translational potential and challenges of IONPs will also be discussed.In conclusion,ongoing research and development of IONP-based strategies are highly likely to address current challenges effectively,and offer more personalized and efficient options for the diagnosis and treatment of CVDs.展开更多
基金This study was supported by the National Natural Science Foundation of China,No.81801239(to DL),China Postdoctoral Science Foundation,No.2019M651165(to DL)Doctoral Start-up Foundation of Liaoning Province of China,No.20180540041(to DL).
文摘Batroxobin is a thrombin-like serine protease from the venom of the Bothrops atrox and Bothrops moojeni snake species.Sirtuin 1(Sirt1)has been shown to play an important role in neuroprotection after traumatic brain injury.However,its underlying mechanism of action remains poorly understood.The purpose of this study was to investigate whether the mechanism by which batroxobin participates in the activation of astrocytes is associated with Sirt1.Mouse models of nigrostriatal pathway injury were established.Immediately after modeling,mice were intraperitoneally administered 39 U/kg batroxobin.Batroxobin significantly reduced the expression of cleaved caspase-3 in both the substantia nigra and striatum,inhibited neuronal apoptosis,and promoted the recovery of rat locomotor function.These changes coincided with a remarkable reduction in astrocyte activation.Batroxobin also reduced Sirt1 expression and extracellular signal-regulated kinase activation in brain tissue.Intraperitoneal administration of the Sirt1-specific inhibitor EX527(5 mg/kg)30 minutes prior to injury could inhibit the abovementioned effects.In mouse astrocyte cultures,1 ng/mL batroxobin attenuated interleukin-1β-induced activation of astrocytes and extracellular signal-regulated kinase.EX527 could also inhibit the effects of batroxobin.These findings suggest that batroxobin inhibits astrocyte activation after nigrostriatal pathway injury through the Sirt1 pathway.This study was approved by the Animal Ethics Committee of China Medical University,China(approval No.CMU2020037)on July 19,2015.
文摘Despite advances in diagnostic and therapeutic technologies for cardiovascular diseases(CVDs),it remains a leading cause of mortality and morbidity worldwide.This underscores the urgency for innovative approaches aiming at early and precise detection and treatment of CVDs to reduce the disease burden.Iron oxide nanoparticles(IONPs),with their unique magnetism and bioproperties,have shown great potential in this regard.In this review,we will begin with a brief overview of the synthesis and properties of IONPs.We will then focus on the latest applications of IONPs in CVDs,including diagnosis and treatment.The use of IONPs in the integration of diagnosis and treatment for CVDs is a promising field,and will be addressed in a separate section.The translational potential and challenges of IONPs will also be discussed.In conclusion,ongoing research and development of IONP-based strategies are highly likely to address current challenges effectively,and offer more personalized and efficient options for the diagnosis and treatment of CVDs.